Bullish Case: Known: UKCA/EU marking and US Medicare coverage for pre-surgical MRD, alongside call-heavy/high-IV options. Inferred from PSNL return-surface: densest likelihood sits near modest outcomes (roughly -10% to +30% for 0–2y holds), so upside is more likely gradual than explosive—consistent with your later “modest rerate” beats the earlier Feb “rapid +80%.” Uncertain: whether MRD adoption converts to sustained revenue/guidance.

Bearish Case: Known: options are extremely IV-rich with crowded calls; recent momentum is up sharply from weeks/months ago. Inferred from SPY volatility surface: elevated macro uncertainty persists across near-term days and downside strikes, making mean reversion drawdowns more abrupt. Uncertain: dilution/guide compression and the durability of Medicare-linked adoption. This aligns with your earlier “tail risk” warnings that downside can be sharp even if deep crashes haven’t shown up yet.

Potential Outcomes:

1. -5..+25% (45%): MRD adoption steady; no secondary; SPY IV stays elevated so mean-reversion favors modest drift toward PSNL return-surface warm band.
2. +15..+50% (30%): guidance/ordering accelerate after Medicare+UKCA commercialization.
3. +60..+140% (10%): credible deal signal (e.g., Tempus) appears in filings/news.
4. -25..-50% (10%): secondary or missed revenue cadence.
5. -50..-90% (5%): Medicare/reimbursement reversal or adverse MRD/clinical data.

Trading Oracle:

Bullish Long Volatility (cheap convexity) for PSNL

Why: With PSNL call-heavy, very high near-term IV and PSNL’s return surface concentrating on modest moves, the edge is in capturing volatility expansion/whipsaw rather than betting on direction. The SPY IV surface suggests macro vol remains elevated, so a defined-risk long-vol call spread aims to benefit if upside resumes or if risk-off increases realized volatility.

July 17, 2026